Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17433846 | 0.92 | PDE10A (0.47) | PDE10AKMT2AATMNCF1MAPT | |
| SCHEMBL17471670 | 0.89 | PDE10A (0.44) | PDE10AKMT2AATMMAPTHCRTR1 | |
| SCHEMBL17434154 | 0.81 | BACE1 (0.44) | PDE10AKMT2AATMNCF1MAPT | |
| SCHEMBL17434024 | 0.80 | PDE10A (0.47) | PDE10AKMT2AATMMAPTHCRTR1 | |
| SCHEMBL17434136 | 0.77 | PDE10A (0.53) | PDE10AMAPTHCRTR1HCRTR2POLB | |
| SCHEMBL17433794 | 0.76 | KMT2A (0.54) | KMT2AATMMAPTBACE1POLB | |
| SCHEMBL17434069 | 0.73 | PDE10A (0.43) | PDE10AKMT2AATMNCF1BACE1 | |
| SCHEMBL17433767 | 0.70 | BACE1 (0.51) | KMT2ANCF1MAPTBACE1POLB | |
| SCHEMBL17433795 | 0.69 | KDM4E (0.52) | KMT2AATMNCF1MAPTBACE1 | |
| SCHEMBL17433834 | 0.69 | SMN1; SMN2 (0.44) | PDE10AKMT2AATMMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | PDE10A, PDE5A, PDE3B | PDE10A 1/4885KMT2A 2674/4885ATM 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.